Edwards Lifesciences Corporation [NYSE: EW] price surged by 0.29 percent to reach at $0.31. The company report on June 2, 2021 that Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff.
Edwards Lifesciences (NYSE: EW) announced that Acumen Hypotension Prediction Index (HPI) software with the Acumen IQ finger cuff has received U.S. Food and Drug Administration clearance. This is the first noninvasive solution that unlocks Acumen HPI software and uses machine learning to alert clinicians of the likelihood a patient is trending toward hypotension, or low blood pressure. Until now, Acumen HPI software has only been available for patients using an invasive arterial line.
“Numerous studies, including our research, have demonstrated an association between intraoperative hypotension and increased risk of acute kidney injury, myocardial injury and even death,” said Kamal Maheshwari, M.D., MPH, anesthesiologist from Cleveland Clinic Foundation. “The noninvasive Acumen IQ cuff provides the opportunity to reduce hypotension in a broader range of patients, including those who do not require an invasive arterial line. The cuff, along with the predictive capabilities of Acumen HPI software to proactively manage hypotension, will have a meaningful impact on patients.”.
A sum of 1786783 shares traded at recent session while its average daily volume was at 2.57M shares. Edwards Lifesciences Corporation shares reached a high of $108.29 and dropped to a low of $106.11 until finishing in the latest session at $108.19.
The one-year EW stock forecast points to a potential downside of -8.19. The average equity rating for EW stock is currently 2.20, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Edwards Lifesciences Corporation [EW]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EW shares is $100.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EW stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Edwards Lifesciences Corporation shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 25, 2021. While these analysts kept the previous recommendation, Atlantic Equities raised their target price to Neutral. The new note on the price target was released on April 15, 2021, representing the official price target for Edwards Lifesciences Corporation stock.
The Average True Range (ATR) for Edwards Lifesciences Corporation is set at 1.77, with the Price to Sales ratio for EW stock in the period of the last 12 months amounting to 14.78. The Price to Book ratio for the last quarter was 14.48, with the Price to Cash per share for the same quarter was set at 2.18. Price to Free Cash Flow for EW in the course of the last twelve months was 92.23 with Quick ratio for the last quarter at 2.90.
EW Stock Performance Analysis:
Edwards Lifesciences Corporation [EW] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.46. With this latest performance, EW shares gained by 11.56% in over the last four-week period, additionally plugging by 24.07% over the last 6 months – not to mention a rise of 57.34% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EW stock in for the last two-week period is set at 77.06, with the RSI for the last a single of trading hit 81.35, and the three-weeks RSI is set at 73.61 for Edwards Lifesciences Corporation [EW]. The present Moving Average for the last 50 days of trading for this stock 97.37, while it was recorded at 106.79 for the last single week of trading, and 87.40 for the last 200 days.
Insight into Edwards Lifesciences Corporation Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Edwards Lifesciences Corporation [EW] shares currently have an operating margin of +29.55 and a Gross Margin at +74.94. Edwards Lifesciences Corporation’s Net Margin is presently recorded at +18.77.
Return on Total Capital for EW is now 25.67, given the latest momentum, and Return on Invested Capital for the company is 16.40. Return on Equity for this stock inclined to 18.88, with Return on Assets sitting at 12.00. When it comes to the capital structure of this company, Edwards Lifesciences Corporation [EW] has a Total Debt to Total Equity ratio set at 15.19. Additionally, EW Total Debt to Total Capital is recorded at 13.19, with Total Debt to Total Assets ending up at 9.60. Long-Term Debt to Equity for the company is recorded at 14.60, with the Long-Term Debt to Total Capital now at 12.67.
Reflecting on the efficiency of the workforce at the company, Edwards Lifesciences Corporation [EW] managed to generate an average of $55,262 per employee. Receivables Turnover for the company is 7.30 with a Total Asset Turnover recorded at a value of 0.64.Edwards Lifesciences Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 3.80.
EW Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EW. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Edwards Lifesciences Corporation go to 15.31%.
Edwards Lifesciences Corporation [EW] Insider Position Details
There are presently around $55,120 million, or 85.60% of EW stock, in the hands of institutional investors. The top three institutional holders of EW stocks are: BLACKROCK INC. with ownership of 57,141,450, which is approximately -2.483% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 48,468,576 shares of the stock with an approximate value of $5.24 billion in EW stocks shares; and STATE STREET CORP, currently with $2.78 billion in EW stock with ownership of nearly -0.521% of the company’s market capitalization.
Positions in Edwards Lifesciences Corporation stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 526 institutional holders increased their position in Edwards Lifesciences Corporation [NYSE:EW] by around 29,106,790 shares. Additionally, 477 investors decreased positions by around 34,301,959 shares, while 231 investors held positions by with 446,066,201 shares. The mentioned changes placed institutional holdings at 509,474,950 shares, according to the latest SEC report filing. EW stock had 99 new institutional investments in for a total of 4,768,124 shares, while 107 institutional investors sold positions of 3,438,037 shares during the same period.